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Widespread genetic modification of cells in the central nervous system (CNS) with a
viral vector has become possible and increasingly more efficient. We previously applied
an AAV9 vector with the cytomegalovirus/chicken beta-actin (CBA) hybrid promoter and
achieved wide-scale CNS transduction in neonatal and adult rats. However, this method
transduces a variety of tissues in addition to the CNS. Thus we studied intravenous
AAV9 gene transfer with a synapsin promoter to better target the neurons. We noted in
systematic comparisons that the synapsin promoter drives lower level expression than
does the CBA promoter. The engineered adeno-associated virus (AAV)-PHP.B serotype
was compared with AAV9, and AAV-PHP.B did enhance the efficiency of expression.
Combining the synapsin promoter with AAV-PHP.B could therefore be advantageous in
terms of combining two refinements of targeting and efficiency. Wide-scale expression
was used to model a disease with widespread pathology. Vectors encoding the
amyotrophic lateral sclerosis (ALS)-related protein transactive response DNA-binding
protein, 43 kDa (TDP-43) with the synapsin promoter and AAV-PHP.B were used for
efficient CNS-targeted TDP-43 expression. Intracerebroventricular injections were also
explored to limit TDP-43 expression to the CNS. The neuron-selective promoter and the
AAV-PHP.B enhanced gene transfer and ALS disease modeling in adult rats.
Keywords: adeno-associated virus, amyotrophic lateral sclerosis, gene therapy, gene transfer, promoter,
synapsin promoter, targeting, TDP-43
INTRODUCTION
Adeno-associated virus (AAV) is one of the most widely used systems for gene transfer to the
central nervous system (CNS), for example in optogenetics, cre-lox targeting, and CRISPR gene
editing. Scientists wishing to genetically modify the brain with AAV often ask: (1) which AAV
serotype should I use in my gene transfer experiments; (2) which promoter/expression cassette
should I be using; and (3) which route of vector administration gives me the transduction
pattern with the greatest disease relevance for my gene of interest? Many of these governing
parameters of AAV gene transfer have been extensively studied with focal, intraparenchymal
injections. However, few of these comparative studies have been made for wide-scale CNS
transduction where neurons are transduced throughout the nervous system. Wide-scale CNS
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transduction is relevant for modeling and treating CNS
diseases with widespread CNS pathology, so optimization
of wide-scale gene transfer is important for these goals.
This study attempted to improve upon previous work with
AAV9 and the hybrid cytomegalovirus/chicken beta-actin (CBA,
also known as the CAG promoter) promoter in terms of
neuronal targeting and gene transfer efficiency. If possible, then
these refinements could be applied to disease modeling and
gene therapy.
If neuronal targeting is the goal, then an appropriate
cell-type specific promoter is necessary. Synapsin is considered
to be a neuron-specific protein (DeGennaro et al., 1983),
so its neuron-specific expression pattern could potentially be
harnessed to express transgenes in a neuron-specific manner.
A minimal human synapsin promoter has been used in
adenoviral and AAV vectors for focal injections (Kügler
et al., 2003a,b; Shevtsova et al., 2005). An AAV capsid
that can reach the CNS after peripheral administration, such
as AAV9 (Foust et al., 2009; Wang et al., 2010; Miyake
et al., 2011) or other natural AAV serotypes (Miyake et al.,
2011; Snyder et al., 2011; Samaranch et al., 2013; Yang
et al., 2014; Jackson et al., 2015b) is advantageous for a
relatively non-invasive administration that yields wide-scale
expression. Now there are several engineered capsids with
increased neuronal transduction efficiency (Choudhury et al.,
2016a,b; Deverman et al., 2016). Here we tested AAV-
PHP.B described in Deverman et al. (2016) in rats for
the first time in order to achieve greater gene transfer
efficiency and potentially for improved neuronal targeting
as well.
The goal of the study was to achieve more efficient CNS
transduction in a more targeted manner than our previous
studies using AAV9 in rats for the purpose of disease modeling.
Transactive response DNA-binding protein, 43 kDa (TDP-43)
is an RNA binding protein that is associated with amyotrophic
lateral sclerosis (ALS): TDP-43 mutations can cause ALS (Gitcho
et al., 2008), and the vast majority of ALS patients harbor
TDP-43 neuropathology in post-mortem studies (Mackenzie
et al., 2007). We have used the CBA promoter to express
TDP-43 before, but here we attempted to better delimit the
TDP-43 expression to neurons using the synapsin promoter
and intracerebroventricular injections. We studied synapsin
promoter-TDP-43 vectors and intracerebroventricular injections
in order to address whether the motor paralysis that we
see using the CBA promoter is due to TDP-43 expression
in the CNS. We also studied AAV-PHP.B TDP-43 vectors
since the greater efficiency could lower vector doses needed,
which could decrease side effects in the animal and save
costs in terms of the amount of vector production that is
required. Furthermore, it is better to model an adult onset
disease such as ALS in an adult onset animal model. Because
adult CNS transduction requires larger amounts of vector
relative to transduction of neonates, more efficient vectors will
facilitate work in disease-relevant adult subjects. We hope these
encouraging results with the synapsin promoter and AAV-
PHP.B will help investigators in their design of wide-scale gene
transfer studies.
MATERIALS AND METHODS
DNA and Viruses
cDNA for green fluorescent protein (GFP) or human wild-type
TDP-43 were incorporated into an expression cassette plasmid
including the AAV2 terminal repeats, the CBA promoter,
(1.8 kb), the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE), and the bovine growth hormone
polyadenylation sequence (Klein et al., 2002). The strong CBA
promoter was first incorporated into an AAV vector by Xu
et al. (2001). The term CBA promoter is synonymous with the
CAG promoter (Niwa et al., 1991). A plasmid for a minimal
human synapsin promoter (485 bp) driving expression of
yellow fluorescent protein (YFP) was provided by K. Deisseroth,
Stanford University. This plasmid also contains the WPRE
and human growth hormone polyadenylation sequence. Two
different fluorophores were used in this study, GFP and the
GFP variant, YFP. YFP should be at least as bright or a brighter
fluorophore than GFP (Ormö et al., 1996; Yang et al., 1996).
The difference in brightness between the two fluorophores had
no bearing on the results particularly since the tissues were
immuno-labeled with a GFP antibody that recognizes both
proteins. cDNA for human wild-type TDP-43 (gene accession
number NM_007375) was also incorporated into the synapsin
promoter cassette in place of YFP.
DNAs were packaged into recombinant AAV9 or AAV-
PHP.B by described methods (Klein et al., 2008b). Helper and
AAV9 capsid plasmids used to generate AAV9 were from the
University of Pennsylvania (Gao et al., 2004). AAV-PHP.B
capsid plasmids were from the California Institute of Technology
(Deverman et al., 2016). Viral stocks were sterilized using a
Millipore Millex-GV syringe filter, aliquoted and stored frozen.
Viral genome copies were titered using dot-blot assay, and equal
titer doses were obtained by diluting stocks in lactated Ringer’s
solution (Baxter Healthcare).
Neonatal Studies
Litters of Sprague-Dawley rats (Envigo) were injected on
post-natal day one. A total of 25 neonatal rats were used
including bothmale and female subjects. Animals received 100µl
of virus diluted in lactated Ringer’s solution administered via a
30 g needle into the facial vein, as previously described (Wang
et al., 2010). The paws of the animals were tattooed (Spaulding
Color, Voorheesville, NY, USA) for identification, and the pups
were weaned at 3 weeks of age. The vector doses for neonates
are expressed as total vector genomes (vg) injected. The neonatal
rats usually weighed 6 g, so the per kg dose is 167 times higher
than the total vg injected. Eleven neonatal rats were injected
with AAV9 synapsin promoter-YFP at a dose of 4 × 1012 vg.
Five animals were administered AAV9 CBA-GFP at a dose
of 1.9 × 1012 vg, and four additional rats were administered
AAV-PHP.B CBA-GFP at an equivalent dose of 1.9× 1012 vg.
Adult Studies
Adult female Sprague-Dawley rats (approximately 6 weeks
of age weighing 130 g, Envigo) were used for intravenous
administrations. A total of 21 subjects were used. For tail
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vein injections, animals received 200 µl of virus diluted in
lactated Ringer’s solution administered via a 30 g needle into
the lateral tail vein. Intravenous delivery was also performed via
retro-orbital injections in a subset of animals. For retro-orbital
injections, animals received 100 µl of diluted virus administered
via a 30 g needle into the capillary bed behind the eye. We
were interested in this method to find an easier or more
reliable method than tail vein injections. The retro-orbital
injections yielded consistent results, but overall we did not
notice any obvious, clear-cut advantage compared to the tail
vein method in adult rats. Four adult rats were administered
AAV9 CBA-GFP at a dose of 1 × 1013 vg/kg and one at a
higher dose of 7.5 × 1013 vg/kg. Four rats were administered
AAV9 synapsin promoter-YFP at a dose of 1 × 1013 vg/kg and
one rat at a higher dose of 7.5 × 1013 vg/kg. Three rats were
administered AAV-PHP.B synapsin promoter-YFP at a dose of
3.8× 1013 vg/kg.
One adult female Sprague-Dawley rat (225 g) was
stereotaxically administered AAV into the substantia nigra
(coordinates: 5.3 mm posterior to bregma, 2.1 mm lateral,
7.6 mm ventral). One side was injected with AAV9 CBA-GFP
and the other side with AAV9 synapsin promoter-YFP at
matching doses (3 × 109 vg). Two adult female Sprague-Dawley
rats (approximately 225 g) were stereotaxically administered
AAV9 into the lateral ventricle (coordinates: 0.93 mm posterior
to bregma, 1.6 mm lateral, 3.5 mm ventral).
Disease Modeling With TDP-43
To demonstrate the relevance of the GFP results for disease
modeling, we administered a subset of rats with TDP-43 vectors.
When AAV9 encoding TDP-43 driven by the CBA promoter
is administered intravenously to either neonatal (Wang et al.,
2010) or adult (Jackson et al., 2015b) rats, a progressive paresis
and paralysis of the limbs develops, which may also involve
mortality depending on the vector dose used (Jackson et al.,
2015b). We have studied rats from 2 to 24 weeks after AAV9
TDP-43 gene transfer (Dayton et al., 2013). TDP-43 is known
to induce paralysis, and at a high vector dose, mortality in
rats, so we purposefully used small numbers of subjects to
determine the presence of the disease state on a yes-or-no
basis. Three neonatal rats were administered AAV9 synapsin
promoter-TDP-43 at a dose of 4 × 1012 vg. Two neonatal
rats were administered AAV-PHP.B-TDP-43 at a dose of
1.6× 1012 vg. Three adult rats were administered AAV9 synapsin
promoter-TDP-43 at a dose of 3 × 1013 vg/kg, and three
rats were administered AAV-PHP.B synapsin promoter-TDP-43
at an equivalent dose of 3 × 1013 vg/kg. These rats were
evaluated for motor dysfunction and mortality. All animal
research conducted was approved by the Animal Care and Use
Committee at Louisiana State University Health Sciences Center
at Shreveport.
Analysis of Motor Function
Animals were evaluated for motor function via rotarod and
escape reflex testing. Rotarod testing was performed on a Rotarod
(Rota-rod/RS, Letica Scientific Instruments, Barcelona, Spain)
that was accelerating from 4 to 40 rpm over 2 min. The amount
of time the rat could remain walking on the rotarod before falling
was measured three times and averaged. The escape reflex was
evaluated by briefly lifting the rat from the tail. A normal escape
reflex is the extension of forelimbs and hindlimbs. Clenching of
the fore- or hindlimbs during this test is indicative of a lesion in
the motor pathway. Motor deficits for the animals administered
TDP-43 were noted if the averaged rotarod scores were less than
30 s or if limb clenching was demonstrated on three consecutive
trials.
Immunohistochemistry
Animals were anesthetized with a cocktail of ketamine
(100 mg/ml, Fort Dodge Animal Health, Fort Dodge, IA,
USA), xylazine (20 mg/ml, Butler, Columbus, OH, USA), and
acepromazine (10 mg/ml, Boerhinger Ingelheim, St. Joseph, MO,
USA) in a 3:3:1 fluid ratio. Animals were administered 2 ml/kg of
the cocktail intramuscularly before perfusion. The animals were
transcardially perfused with phosphate buffered saline followed
by cold 4% paraformaldehyde in phosphate-buffered saline.
Tissues were removed and immersed in 4% paraformaldehyde
overnight at 4◦C. Tissues were cryopreserved in 30% sucrose.
Fifty µm sections were cut on a sliding microtome with a
freezing stage (Leica Biosystems, Buffalo Grove, IL, USA). The
primary antibodies were rabbit anti-GFP (Invitrogen, 1:500),
mouse anti-GFP (Invitrogen, 1:250), which efficiently label
both GFP and YFP, rabbit anti-glial fibrillary acidic protein
(GFAP; Chemicon, 1:1000) which labels astrocytes, mouse
anti-CD11B (Chemicon, 1:500) which labels microglia, and
mouse anti-NeuN (Chemicon, 1:1000) which labels neurons. The
secondary antibodies were Alexa Fluor 488 and Alexa Fluor 594
(Invitrogen) at a concentration of 1:300. DAPI (Sigma, St. Louis,
MO, USA) was used as a counterstain.
Analysis of Transgene Expression in The
Cerebellum
After immunofluorescent staining for GFP, three evenly
spaced sections of the cerebellar vermis for each animal
were photomicrographed using a 2.5× lens and converted
to grayscale. The fluorescent area was quantified using Scion
Image as previously described (Jackson et al., 2015b), and the
three sections per animal were averaged. We confirmed that
non-transduced tissues had only negligible background readings
by analyzing cerebellum that was not transduced with AAV but
stained for GFP.
RESULTS
Promoter Studies
Transgene Expression Pattern of Synapsin
Promoter-AAV9
A neonatal rat receiving AAV9 synapsin promoter-YFP
intravenously at a dose of 4 × 1012 vg (6.7 × 1014 vg/kg) was
evaluated at 4 weeks for CNS expression. Robust, wide-scale
expression in the CNS was achieved with efficient labeling of
neurons in the frontal cortex, forebrain, cerebellum and spinal
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FIGURE 1 | Highly efficient wide-scale central nervous system (CNS)
transgene expression in the rat using the synapsin promoter with
avoidance of heart, but not liver expression. Synapsin promoter-AAV9
was administered intravenously to a neonatal rat and the tissue was analyzed
4 weeks later. (A,B) Expression in cortical neurons. (C) Hippocampus.
(D) Striatum. (E) Cerebellum. (F,G) Spinal cord. (H) The heart had trace to no
expression. (I) The synapsin promoter-AAV9 did result in expression in the
liver. (J) This synapsin promoter DNA construct also drives expression in
non-neuronal cells (HEK 293T) after transfection. Green fluorescent protein
(GFP) immunostaining in (A–I) Native fluorescence in (J) Bar in (A) = 268 µm,
same magnification in (E,F,H–J) Bar in (B) = 134 µm, same magnification in
(C,D,G–I).
cord among other regions throughout the CNS (Figures 1A–G).
In the CNS, the transduced cells appeared exclusively neuronal
and did not include cells with glial morphologies. The YFP
expressed in transduced cells did not co-localize with GFAP, an
FIGURE 2 | Transgene expression profiles in astroglia, microglia, and
neurons in the CNS. Pictures are mergers of GFP immunofluorescence in
green and cell type specific markers in red, from the hippocampus. (A,B) For
astroglia (glial fibrillary acidic protein, GFAP), there were occasional examples
of GFP-positive cells with the cytomegalovirus/chicken beta-actin hybrid
(CBA) promoter (arrow) but GFP-positive astroglia were not present using the
synapsin promoter. (C,D) For microglia (CD11B), the adeno-associated virus
(AAV) transgene did not co-localize with the microglial marker with either
promoter. (E,F) Most of the cells expressing the transgene in the CNS were
co-labeled with the neuronal marker NeuN with either the CBA or synapsin
promoter. AAV-PHP.B was used for both promoters and the expression
interval was 4 weeks after intravenous administration. Bar in (A) = 42 µm,
same magnification in (A–F).
astrocyte marker, or CD11B, a microglia marker (Figure 2). By
comparison, the CBA promoter drives expression in occasional
astroglia, though mostly expresses in neurons in the CNS
(Figure 2). Outside of the CNS, with the synapsin promoter, the
cardiomyocytes were largely spared from transgene expression
(Figure 1H), a clear success of this promoter strategy as we
were attempting a more restricted pattern compared to the CBA
promoter, which efficiently expresses in cardiomyocytes (Wang
et al., 2010). However, synapsin promoter driven YFP was
observed in the liver at 4 weeks (Figure 1I), so the recombinant
human synapsin promoter should therefore be referred to
as neuron-selective, not neuron-specific in the context of a
recombinant AAV9 vector. Along these lines, during the vector
packaging stages, the synapsin promoter expressed in the
non-neuronal HEK 293T cells (Figure 1J). Comparing on a
qualitative basis with the heart and liver expression conferred by
the CBA promoter in rats (Wang et al., 2010), expression in the
heart appears to be nearly completely silenced with the synapsin
promoter and partially muted in the liver.
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Comparison of the Synapsin Promoter with the CBA
Promoter
The two promoters, synapsin and CBA, were evaluated for CNS
expression levels. One Sprague-Dawley rat was administered
AAV9 CBA promoter-GFP on one side of the brain and on
the other side, AAV9 synapsin promoter-YFP, each at an equal
vector dose of 3× 109 vg. After 3 weeks, the substantia nigra was
analyzed for fluorescence, which clearly supported that the CBA
promoter drives stronger expression than the synapsin promoter
under equal conditions (Figures 3A,B). We then compared the
CBA and synapsin promoters in adult rats on a statistical basis,
using intravenous gene delivery by the retro-orbital injection
method. Each of the two promoter constructs was administered
at an equal dose of 1 × 1013 vg/kg. The CBA promoter
group produced greater expression in the cerebellum compared
to the synapsin promoter group by 5.6-fold (Figures 3C–I;
t-test, n = 3/promoter group, p < 0.01, expression interval of
4 weeks).
Attenuation of Long-Term Expression with the
Synapsin Promoter
The CBA promoter is known to confer high expression levels on
a long-term basis, for example 1 year in rats in Klein et al. (2002)
and 8 months in non-human primates in Jackson et al. (2015a).
To determine if expression driven by the synapsin promoter
remained stable over time, 11 neonatal rats were administered
AAV9 synapsin promoter-YFP at a dose of 4 × 1012 vg
(6.7 × 1014 vg/kg). Five of the rats were evaluated at 4 weeks,
and the remaining six were evaluated at 22 weeks. Transduction
of the cerebellum was evaluated, which clearly demonstrated
attenuation of synapsin promoter driven expression at the longer
interval (Figure 4; t-test, n = 5–6/time point, p< 0.01).
Studies With The AAV-PHP.B Capsid
CBA Promoter-AAV-PHP.B, Comparison with AAV9 in
Neonates
AAV-PHP.B was reported to be 40-fold more efficient than
AAV9 for neuronal transduction in mice by Deverman et al.
(2016). Here, we made a comparison in rats using the same CBA
promoter expression cassette in AAV9 or AAV-PHP.B. Four
neonatal animals were administered AAV-PHP.B CBA-GFP and
five neonatal animals with AAV9 CBA-GFP at an equal vector
dose of 1.9 × 1012 vg (3.2 × 1014 vg/kg). Expression was
evaluated 4 weeks later. The transduction of the cerebellum
was increased by 2.4-fold in the AAV-PHP.B group compared
to the AAV9 group (Figure 5; t-test, n = 4–5/capsid serotype
group, p < 0.001). The lesser degree of fold-increase observed
in rats compared to mice (Deverman et al., 2016) could be
due to making this comparison closer to the vector dose
saturation point in neonates. Since large doses of highly efficient,
high titer AAV9 vectors are needed for wide-scale studies in
adult subjects, the increased transduction efficiency of AAV-
PHP.B should be able to lower this demand and save on the
amount of vector production needed. Though not quantified,
there was a visible trend of reduced hepatic expression using
AAV-PHP.B compared to AAV9 along with the increased
FIGURE 3 | In comparisons of the synapsin promoter and the CBA
promoter, the CBA promoter clearly drives stronger expression. One
rat received a bilateral stereotaxic injection into the substantia nigra. One side
was injected with a synapsin promoter-AAV9 and the other with a CBA
promoter-AAV9 under equal conditions. (A,B) The expression from the
synapsin promoter-AAV9, while present, was fainter than the CBA
promoter-AAV9 at equal camera exposures. (C–H) Similarly, after retro-orbital
injections of AAV9 in adult rats under equal conditions, the expression from
the synapsin promoter-AAV9 appeared fainter than the CBA promoter-AAV9,
cerebellum in (C,D) spinal cord in (E–H). (I) The GFP-positive area of the
cerebellum was greater in the CBA promoter-AAV9 group (t-test, p < 0.01,
n = 3/promoter group). GFP immunostaining in (C–H). Bar in (A) = 134 µm,
same magnification in (B). Bar in (C) = 536 µm, same magnification in (D–F).
Bar in (G) = 67 µm, same magnification in (H). ∗ Indicated p < 0.01.
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FIGURE 4 | Attenuation of synapsin promoter-driven expression at 22 weeks post gene transfer. Neonatal rats were administered synapsin promoter-AAV9
intravenously and the tissues were analyzed at time points of either 4 (A) or 22 (B) weeks. (C) The area of the cerebellum positive for GFP was compared. Lower
level expression was found at the later time point (t-test, p < 0.01, n = 5–6 /per interval). GFP immunostaining in (A,B). Bar in (A) = 536 µm, same magnification in
(B). ∗ Indicates p < 0.01.
neuronal expression. These results are therefore consistent with
the hypothesis that AAV-PHP.B is advantageous for neuronal
targeting as well as greater efficiency.
Synapsin Promoter-AAV-PHP.B in Adults
Based on the increased transduction observed with AAV-PHP.B
in neonates, we administered three adult animals with AAV-
PHP.B synapsin promoter-YFP at a dose of 3.8 × 1013 vg/kg,
and the tissues were analyzed 4 weeks later. Neuronal expression
was achieved in the cerebellum and spinal cord (Figures 6A,B).
There appeared to be no expression in the heart (Figure 6C)
and some expression in the liver (Figure 6D), at a lower
level than would be expected using the CBA promoter. AAV-
PHP.B should therefore be advantageous to boost the expression
of a weaker promoter while retaining the promoter tissue
specificity.
Intracerebroventricular Route of
Administration
We also conducted adult intracerebroventricular administrations
to improve CNS transduction and limit peripheral transduction.
Intra-ventricular AAV injections in mice have been shown
to be advantageous for widespread gene transfer in the
CNS and gene therapy (Lo et al., 1999; Passini and Wolfe,
2001; Li and Daly, 2002; Passini et al., 2003), whereas
intraparenchymal AAV injections in the brain produce more
focal expression (Klein et al., 1998, 2002, 2006, 2008a). One
rat was administered AAV9 CBA promoter-GFP in the lateral
ventricle at a dose of 3.8 × 1012 vg/kg, and tissues were
analyzed 6 weeks later. There was a wide ranging spread
of the GFP expression in the hippocampus, cerebellum and
spinal cord (Figure 7). In the hippocampus of this sample,
pyramidal neurons in CA3/CA4 were transduced, while the
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FIGURE 5 | AAV-PHP.B provides increased transduction efficiency in
the CNS relative to AAV9. Neonatal rats were injected intravenously with the
CBA promoter construct packaged into either AAV9 or AAV-PHP.B under
equal conditions, with a 4 week expression interval. (A,B) There was stronger
GFP expression in the cerebella of rats administered AAV-PHP.B. (C–F) The
same pattern was found in the spinal cord (C,D) and the heart (E,F).
(G,H) Interestingly, AAV-PHP.B did not appear to similarly increase expression
in liver, which is consistent with improved neuronal targeting. (I) GFP-positive
area in the cerebellum (t-test, p < 0.001, n = 4–5/per AAV capsid serotype
group). GFP immunostaining in (A–H). Bar in (A) = 536 µm, same
magnification in (B). Bar in (C) = 67 µm, same magnification in (D). Bar in
(E) = 134 µm, same magnification in (F–H). ∗ Indicates p < 0.001.
CA1 region showed strong GFP expression in the neuropil
though not in pyramidal neuron perikarya. However, a potential
caveat of this approach was the very high degree of expression
FIGURE 6 | Combining advantages for targeting and efficiency in a
synapsin promoter-AAV-PHP.B vector. Neonatal rats were administered
synapsin promoter-AAV-PHP.B intravenously, with an expression interval of
4 weeks. (A) Expression in the cerebellum. (B) Spinal cord. (C) The heart was
blank for expression, as expected. (D) Importantly, the liver showed a relatively
low level expression compared to previous CBA promoter-AAV9 vectors. GFP
immunostaining in (A–D). Bar in (A) = 536 µm. Bar in (B) = 67 µm. Bar in
(C) = 134 µm, same magnification in (D).
in the cortex along the injection track (Figure 7F), since
a large vector dose was used. The cerebrospinal fluid can
exit the CNS into the venous system, so peripheral organ
transduction was examined. There was little transduction
of cardiomyocytes (Figure 7G), but GFP expression in the
liver was clearly evident after intracerebroventricular injections
(Figure 7H).
TDP-43-Induced Phenotypes using the
Synapsin Promoter, AAV-PHP.B and
Intracerebroventricular Delivery
We know that AAV9 wide-scale gene transfer is more efficient
in neonates relative to adults (Jackson et al., 2015b). When
AAV9 synapsin promoter-TDP-43 was administered to a small
group of three neonates, mortality resulted within 2–3 weeks.
A relatively high vector dose was used (4 × 1012 vg or
6.7 × 1014 vg/kg) which would also induce mortality if the
stronger CBA promoter was used (Wang et al., 2010). However,
in a small group of three adult subjects, we did not observe the
typical, progressive motor deficits and paralysis for up to 6 weeks
after administering the AAV9 synapsin promoter-TDP-43 at a
vector dose of 3 × 1013 vg/kg, a dose that is sufficient to induce
the disease state using the CBA promoter in adults (Jackson et al.,
2015b).
AAV-PHP.B CBA promoter-TDP-43 was noticeably stronger
than the AAV9 counterpart in neonates causing severe limb
dysfunction and mortality rapidly, by 10 days (1.6 × 1012 vg
or 2.7 × 1014 vg/kg, n = 2). In adults, in contrast to
AAV9, AAV-PHP.B synapsin promoter-TDP-43 did result in
the characteristic paresis/paralysis of the limbs by 2 weeks
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FIGURE 7 | Intracerebroventricular administration produces far
reaching expression in the CNS with low level expression in liver. An
adult rat was injected with CBA promoter AAV9 into the lateral ventricle. There
was a widespread expression throughout the CNS including the spinal cord in
the lumbar region (A), the hippocampus (B), the cerebellum (C,D), and the
cerebral cortex on the contralateral side (E). (F) There was extremely strong
expression along the needle track into the ventricle. (G) No expression was
seen in the heart. (H) There was some expression in the liver. GFP
immunostaining in (A–H). Bar in (A) = 134 µm, same magnification in (B,H).
Bar in (C) = 536 µm, same magnification in (F). Bar in (D) = 268 µm, same
magnification in (E,G).
post-injection (3 × 1013 vg/kg, n = 3). Both the hindlimbs
and the forelimbs were affected in rats in the AAV-PHP.B
group during the escape reflex, but no such deficits were
noticed in the AAV9 rats. In rotarod testing at 6 weeks
post-injection in adults, there was a difference in fall latency
between the two AAV serotype groups. The time to fall in the
AAV9 synapsin promoter-TDP-43 group was 80.6 ± 10.3 s
(unimpaired) and 22.6 ± 13.5 s in the AAV-PHP.B synapsin
promoter-TDP-43 group (p < 0.05, t-test, n = 3/group). These
results are summarized in Table 1. Interestingly, in one rat
administered AAV9 CBA promoter-TDP-43 into the lateral
ventricle at a dose of 3.8 × 1012 vg/kg, the motor deficits,
limb paralysis, and overall disease state manifested within
2 weeks. Importantly, an almost 10-fold lower vector dose was
used than what we would use for an intravenous vector dose
to induce the disease state with this vector (Jackson et al.,
2015b).
DISCUSSION
Better neuronal targeting of wide-scale gene transfer in rats
was achieved using the synapsin promoter. Better efficiency was
achieved using the AAV-PHP.B capsid. It will be interesting
to combine these two elements since the improved capsid can
make up for the low promoter strength of this tissue-specific
promoter while retaining promoter specificity. This is the
first example of gene transfer with AAV-PHP.B in rats. Rats
are particularly advantageous compared to mice because of
their larger size, because their physiological parameters are
closer to human, and because there are specific behavioral,
pharmacological, and toxicological assays designed for rats.
Furthermore, an increasing amount transgenic rat strains are
becoming available.
Within the CNS, the synapsin promoter-AAV9 appeared to
avoid glial cells. The CBA promoter-AAV9 mostly expressed
in neurons and in some sporadic astroglia. While the synapsin
promoter was clearly not as strong as the CBA promoter,
successful neuronal targeting was achieved. In contrast to the
CBA promoter, the synapsin promoter avoided expression
in cardiomyocytes and appeared to generate less expression
in the liver. Though not absolutely neuron-specific, the
synapsin promoter strategy was successful to mitigate and
minimize the peripheral expression to a substantial extent.
Neuron-selective, but not neuron-specific expression was also
reported by Huda et al. (2014) when they applied a synapsin
promoter-AAV9 vector intravenously to mice. The lack of
complete neuron specificity of the synapsin promoter may
be due to the short recombinant promoter sequence. On
the other hand, the AAV2 inverted terminal repeats are
known to possess weak promoter activity (Flotte et al., 1993;
Haberman et al., 2000) which could be responsible for the
non-neuronal expression. Additionally, some studies have found
synapsin protein and mRNA in the liver (Bustos et al.,
2001) suggesting that endogenous synapsin expression may
not be neuron-specific. In any case, we were able to achieve
quite robust wide-scale transgene expression with the synapsin
promoter-AAV9 in rats for the first time. The efficiency of
the synapsin promoter-driven expression throughout the CNS
shown here is unprecedented. Critically important, and in
contrast to previous results with the CBA promoter, we report
reduced synapsin promoter-driven expression in the long-term
(5–6 months). More work will be needed to confirm this effect
and perhaps determine if the synapsin promoter is subject
to silencing by DNA methylation, for example Prösch et al.
(1996). The lowered expression over time with the synapsin
promoter would probably not affect short-term studies on
the order of 1 month, but could be critical to consider
in long-term studies including neurodegenerative disease
modeling. Furthermore, the widespread, diffuse expression
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TABLE 1 | Outcomes of transactive response DNA-binding protein, 43 kDa (TDP-43)-induced phenotypes in small groups of rats.
Route AAV Promoter Dose N Outcome
Neonatal i.v. AAV9 CBA 2 × 1012 vg 1 Fatal by 2 weeks (Dayton et al., 2013)
Neonatal i.v. AAV9 Synapsin 4 × 1012 vg 3 Fatal by 2–3 weeks
Neonatal i.v. AAV-PHP.B CBA 1.6 × 1012 vg 2 Fatal by 10 days, abnormal limb posture
Adult i.v. AAV9 CBA 3 × 1013 vg/kg 3 Impaired motor function, fatal by 5 weeks post-injection
(Jackson et al., 2015b)
Adult i.v. AAV9 Synapsin 3 × 1013 vg/kg 3 No symptoms up to 6 weeks post-injection
Adult i.v. AAV-PHP.B Synapsin 3 × 1013 vg/kg 3 Impaired motor function by 2 weeks post-injection, p < 0.05 vs.
AAV9 synapsin promoter-TDP-43 on rotarod at 6 weeks
Adult i.c.v AAV9 CBA 3.8 × 1012 vg/kg 1 Impaired motor function by 2 weeks post-injection
pattern after intravenous injections may be more sensitive to
detect reduced expression over time than in stereotaxic injections
which introduce more genome copies per transduced cell. The
relatively low to moderate expression conferred by the synapsin
promoter may be advantageous for achieving physiologically
relevant expression levels, and clearly the synapsin promoter
is advantageous for neuronal targeting with the wide-scale
approach.
We found that AAV-PHP.B yielded higher transduction
efficiency for neurons in rats than AAV9, corroborating the
results in mice in Deverman et al. (2016). We exploited this
critical advantage by coupling the synapsin promoter with AAV-
PHP.B which enabled a phenotype including both forelimb and
hindlimb motor paralysis when expressing TDP-43. We were
unable to observe a phenotype with AAV9 synapsin promoter-
TDP-43 in adult rats, but this hurdle was overcome using
the more efficient AAV-PHP.B, underscoring the utility of the
improved engineered AAVs.
By observing the TDP-43-induced phenotype with the
synapsin promoter in neonates with AAV9 and in neonates
and adults with AAV-PHP.B, we are more confident that the
paralysis is mediated by TDP-43 expression in neurons. We
were somewhat surprised the intracerebroventricular injection
resulted in such far reaching expression in the CNS, although
similar findings have been reported with intra-cerebrospinal
fluid injections in mice, pigs, and monkeys (Snyder et al., 2011;
Federici et al., 2012; Samaranch et al., 2013; Donsante et al.,
2016). We found a mosaic, sporadic labeling of clusters of
Purkinje neurons in the cerebellum after intracerebroventricular
administration, consistent with other studies (Hinderer et al.,
2014; Donsante et al., 2016), which may reflect the flow of
the cerebrospinal fluid. In contrast, the intravenous delivery
produces more evenly distributed transduction in the cerebellum
by comparison. As previously discussed (Gholizadeh et al.,
2013; Samaranch et al., 2013; Donsante et al., 2016), the
intraventricular route of administration is advantageous for
wide-scale CNS transduction because it better limits the
vector to the CNS and requires lower vector doses relative to
intravenous delivery. We also found some degree of hepatic
transduction after intracerebroventricular administration in
rats as seen before in mice and monkeys (Samaranch et al.,
2013; Donsante et al., 2016). We can assume that using the
synapsin promoter and AAV-PHP.B would better avoid this
low level expression in the liver after intracerebroventricular
administration. The intracerebroventricular delivery method
was advantageous for better targeting TDP-43 expression to
the CNS and clearly sufficient to induce the characteristic
phenotype. Thus, the paralysis should be mediated by TDP-43
expression in brain and spinal cord neurons. One caveat
of this study is the low sample size used for the stereotaxic
injection of CBA and synapsin promoter vectors and for
the intracerebroventricular gene transfer. However, we
compared the CBA and synapsin promoters on a statistical
basis after i.v. administration and found a similar pattern
to the focal injection, that the CBA promoter is clearly
stronger. For the intracerebroventricular injections it was
clear that wide-scale expression can be achieved in rats and
that this method permits the characteristic TDP-43 induced
paralysis. We believe that the combination of the synapsin
promoter and AAV-PHP.B will be advantageous to investigators
asking which configuration to use in their studies, given
the improved targeting and efficiency. Though preliminary,
we realized the benefits of an intracerebroventricular route
of administration, while an intravenous delivery is less
invasive. While not absolutely neuron-specific, the synapsin
promoter did produce a highly selective expression pattern
which supports that greater and greater pinpoint targeting
can be achieved even after peripheral administration of
vector.
We conclude that the combination of the synapsin promoter
with AAV-PHP.B is advantageous for neuronal targeting
and efficient expression in adults after peripheral, wide-scale
intravenous delivery. We demonstrated that this combination
was necessary for observing behavioral motor deficits induced by
TDP-43 in adults, with neuron-selective expression. If this design
worked for achieving our goal with TDP-43 here, then synapsin
promoter AAV-PHP.B vectors will probably also permit new
basic and clinical neuroscience approaches that were not possible
before.
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